$57.62
0.24% today
NYSE, Dec 26, 02:54 pm CET
ISIN
US1101221083
Symbol
BMY
Sector
Industry

Bristol-Myers Squibb Stock price

$57.76
-1.02 1.74% 1M
+15.57 36.90% 6M
+6.45 12.57% YTD
+5.47 10.46% 1Y
-4.53 7.27% 3Y
-5.40 8.55% 5Y
-1.39 2.35% 10Y
NYSE, Closing price Wed, Dec 25 2024
+0.00 0.00%
ISIN
US1101221083
Symbol
BMY
Sector
Industry

Key metrics

Market capitalization $117.15b
Enterprise Value $160.51b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 11.63
EV/Sales (TTM) EV/Sales 3.38
P/S ratio (TTM) P/S ratio 2.47
P/B ratio (TTM) P/B ratio 6.83
Dividend yield 4.19%
Last dividend (FY24) $2.42
Revenue growth (TTM) Revenue growth 5.56%
Revenue (TTM) Revenue $47.44b
EBIT (operating result TTM) EBIT $8.36b
Free Cash Flow (TTM) Free Cash Flow $13.80b
Cash position $8.10b
EPS (TTM) EPS $-3.60
P/E forward negative
P/S forward 2.47
EV/Sales forward 3.38
Short interest 1.26%
Show more

Is Bristol-Myers Squibb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.

Bristol-Myers Squibb Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Bristol-Myers Squibb forecast:

8x Buy
29%
19x Hold
68%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Bristol-Myers Squibb forecast:

Buy
29%
Hold
68%
Sell
4%

Financial data from Bristol-Myers Squibb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
47,435 47,435
6% 6%
100%
- Direct Costs 20,935 20,935
12% 12%
44%
26,500 26,500
1% 1%
56%
- Selling and Administrative Expenses - -
- Research and Development Expense 9,818 9,818
6% 6%
21%
18,504 18,504
2% 2%
39%
- Depreciation and Amortization 10,145 10,145
3% 3%
21%
EBIT (Operating Income) EBIT 8,359 8,359
7% 7%
18%
Net Profit -7,258 -7,258
188% 188%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Bristol-Myers Squibb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bristol-Myers Squibb Stock News

Neutral
Business Wire
3 days ago
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--BMS Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis.
Neutral
Business Wire
3 days ago
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult.
Positive
The Motley Fool
5 days ago
Are you looking for reliable long-term investment income? Consider starting your search here, with a closer look at three great dividend stocks that would be at home in nearly any investor's portfolio.
More Bristol-Myers Squibb News

Company Profile

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Head office United States
CEO Christopher Boerner
Employees 34,100
Founded 1933
Website www.bms.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today